胡家朗;郑琼;叶哲伟;勘武生;

• 1:湖北省武汉市普爱医院
• 2:华中科技大学附属协和医院

摘要(Abstract)：

[目的]研究NK92细胞经γ射线辐照后的增殖活性及对HOS骨肉瘤细胞的体外杀伤效应变化;观察rhIL-12对γ射线辐照后NK92细胞的胞毒杀伤效力的影响。[方法]应用60Coγ射线发生器对NK92进行照射处理,照射剂量分别为0,3,10 Gy,靶细胞为K562细胞及HOS细胞,其中K562细胞为阳性对照。MTT法检测NK92细胞经射线受照后的增殖能力及不同处理条件下NK92细胞对靶细胞的杀伤活性。将2 ng/ml rhIL-12加入预照射处理后的NK92培养基中孵育过夜,检测rhIL-12对γ射线辐照后NK92细胞的胞毒杀伤效力的影响,流式细胞术检测细胞表面Fas表达的变化。[结果]随着效靶比梯度的变化,NK92对HOS的杀伤率在4.3%~48.0%之间。与未照射组相比,经射线处理后的NK92细胞对靶细胞的杀伤率差异无统计学意义(P>0.05)。2 ng/ml rhIL-12能明显提高NK92细胞及γ射线辐照后的NK92细胞的体外杀伤作用(P<0.05)。[结论]γ射线辐照后的NK92细胞对HOS细胞具有良好的杀伤活性,同时其自身增殖活性明显降低,可作为骨肉瘤过继免疫治疗的理想效应细胞。此外,rhIL-12能明显提高NK92细胞对靶细胞的杀伤活性,起到良好正向调节作用。

关键词(KeyWords)： NK细胞系;过继免疫治疗;骨肉瘤;IL-12

Abstract:

Keywords:

基金项目(Foundation): 湖北省生物靶向治疗研究重点实验室开放课题资助项目(编号:2007B08)

作者(Author): 胡家朗;郑琼;叶哲伟;勘武生;

Email:

DOI:

参考文献(References)：

• [1]仇志强,廖琦.骨肉瘤治疗的研究进展[J].中国修复重建外科杂志,2010,12:1469-1475.
• [2]何博,常彬.骨肉瘤转移的分子研究进展[J].中国矫形外科杂志,2013,12:159-162.
• [3]Levy EM,Roberti MP,Mordoh J.Natural killer cells in human cancer:from biological functions to clinical applications[J].J Biomed Biotech,2011:1-11.
• [4]陈纲,凌斌,祝怀平,等.自然杀伤细胞系NK92治疗卵巢癌的体外及动物实验研究[J].中华妇产科杂志,2005,7:476-479.
• [5]Geller MA,Miller JS.Use of allogeneic NK cells for cancer immunotherapy[J].Immunotherapy,2011,12:1445-1459.
• [6]Arai S,Meagher R,Swearingen M,et al.Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma:a phase I trial[J].Cytotherapy,2008,6:625-632.
• [7]Buddingh EP,Schilham MW,Ruslan SE,et al.Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells[J].Cancer Immunol Immunother,2011,60:575-586.
• [8]Mori K,Rdini F,Gouin F,et al.Osteosarcoma:current status of immunotherapy and future trends[J].Oncology Reports,2006,15:693-700.
• [9]Broady R,Manganini M,Barbui AM,et al.Stable retroviral transduction and expression of human CD20 gene in NK-92 cell line:a possible innovative tool for cellular immunotherapy[J].Blood,2003,102:2756.
• [10]Sanborn KB,Mace EM,Rak GD,et al.Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity[J].Blood,2011,22:5862-5871.
• [11]Krzewski K,Coligan JE.Coligan.Human NK cell lyticgranules and regulation of their exocytosis[J].Front Immunol,2012,3:1-16.
• [12]Duan XD,Zhou ZC,Jia SF,et al.Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the fas/fas-ligand pathway[J].Clin Cancer Res,2004;10:777-783.
• [13]Dasgupta A,Shields JE,Spencer HT.Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy[J].Human Gene Ther,2012;23:711-721.
• [14]Edsparr K,Johansson BR,Goldfarb RH,et al.Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expression[J].Immunol Cell Biol,2009,87:489-495.
• [15]Mariani E,Meneghetti A,Tarozzi A,et al.Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells:the synergistic effect of interleukin-2[J].Scand J Immunol,2000,51:618-625.
• [16]Sahm C,Schnfeld K,Wels WS.Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modiWed eVectors that carry a tumor-speciWc antigen receptor[J].Cancer Immunol Immunother,2012;61:1451-1461.